# Keith Crandell

> Keith Crandell is a Series A investor at ARCH Venture Partners backing Biotechnology. See 18 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners)
- Location: Chicago, United States
- Total investments: 18
- Last investment: Jan 2026
- Lead investor: 39%
- Last updated: Aug 2026

Keith Crandell is a Series A investor at ARCH Venture Partners in Chicago focused on Biotechnology and Health Care. Keith L. Crandell is based out of Chicago, Illinois, and is the Co-founder and Managing Director of ARCH Venture Partners. Keith previously worked at ARCH Development Corporation as a Senior Manager. Keith L.Crandell attended the University of Chicago.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 56% |
| Health Care | 4 | 22% |
| Medical | 3 | 17% |
| Life Science | 3 | 17% |
| Biopharma | 2 | 11% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 22% |
| Series B | 4 | 22% |
| Series C | 4 | 22% |
| Series D | 2 | 11% |
| Angel | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 44% |
| China | 1 | 6% |
| Canada | 1 | 6% |
| Singapore | 1 | 6% |
| United Kingdom | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vizgen | Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. | $48M | Series E | Jan 08, 2026 |  |
| Arbor Biotechnologies | Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases. The company utilizes artificial intelligence and high-throughput screening to discover and optimize novel gene-editing systems. Its research focuses on expanding the CRISPR-based gene editing toolbox for therapeuticapplications. Arbor aims to develop treatments for rare and complex diseases by engineering precise and efficient genetic modifications. | $73.9M | Series C | Mar 18, 2025 |  |
| AIRNA | AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments. | $60M | Series A | Jul 31, 2024 |  |
| UltraDx Bio | UltraDx Bio is a biotechnology company that specializes in single-molecule digital high-sensitivity protein detection technology. | $13.7M | Angel | Nov 08, 2023 |  |
| AIRNA | AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments. | $30M | Series A | Sep 19, 2023 |  |
| ONI | ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world's first benchtop sized super-resolution microscope, delivers a step change in usability and precision. This, together with our next-generation consumable products will empower academicresearchers, clinicians and scientists to on a path to discovery.The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal.The company's achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard.ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. Our vision is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand and share the microscopic details of life. | $75M | Series B | Dec 24, 2021 |  |
| Ultivue | Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts. | $50M | Series D | Apr 27, 2021 |  |
| One BioMed | One BioMed is a medical diagnostics company | $5M | Series A | Jul 10, 2019 |  |
| Ultivue | Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts. | $22M | Series C | Jun 14, 2019 |  |
| Ultivue | Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts. |  | Series B | Jan 23, 2018 |  |

10 of 18 investments shown.

## Co-investors
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 5 deals together
- [Applied Ventures](https://shizune.co/investors/profile/applied-ventures) — VC Fund, 3 deals together
- [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 2 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 2 deals together
- [Bain Capital Ventures](https://shizune.co/investors/profile/bain-capital-ventures) — VC Fund, 2 deals together
- [Credit Suisse](https://shizune.co/investors/profile/credit-suisse) — VC Fund, 2 deals together

## About ARCH Venture Partners

VC Fund · Chicago, United States

ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories.ARCH has raised ten venture fundstotaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

5 contacts available at ARCH Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Cindy Bayley | Affiliate | https://shizune.co/investors/profile/cindy-bayley |
| Clinton Bybee | Co-Founder and Managing Director | https://shizune.co/investors/profile/clinton-w-bybee |
| Hong Hou | Venture Partner | https://shizune.co/investors/profile/hong-hou |
| Keith Crandell | Co-founder & Managing Director | https://shizune.co/investors/profile/keith-l-crandell |
| Kristina Burow | Managing Director | https://shizune.co/investors/profile/kristina-burrow |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Keith Crandell invest in?

Keith Crandell invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Keith Crandell last invest?

The most recent investment recorded for Keith Crandell closed in Jan 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co